Pulmonary Arterial Hypertension: The Unmet Needs in the Diagnosis and Therapeutic Management
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: 30 October 2024 | Viewed by 51
Special Issue Editors
Interests: vascular diseases; pulmonary arterial hypertension
Special Issue Information
Dear Colleagues,
PAH is a life-threatening syndrome characterized by the remodeling of the distal pulmonary arteries, leading to increased pulmonary vascular resistance, right heart failure and premature death. In the past three decades, there have been significant advancements, leading to novel therapeutic strategies and a better understanding of the pathogenesis of PAH.
Nevertheless, PAH remains an incurable disease. To facilitate decision making on treatment strategy, European PH guidelines have proposed a periodic dynamic risk stratification that plays a key role in choosing the most appropriate treatment strategy, aiming at slowing disease progression. However, the current risk stratification tools may not sufficiently capture the heterogeneity of the disease. Indeed, approximately 60% of patients end up in the intermediate risk class, with an unsatisfactory clinical status, high mortality rate and clinical worsening, thereby highlighting the limited discrimination capacity of current scores. Experts agree that considering additional variables involved in the pathophysiology of PAH could pave the way for personalized treatment, leading to an improved prognosis.
We are pleased to invite you to contribute to this Special Issue with the following aims:
- Define new prognostic markers to improve the risk stratification of PAH patients.
- Guide PAH specialists in the definition of the optimal timing for parenteral prostanoids and/or for lung transplantation.
- Focus on new therapeutic strategies acting on new genetic pathways.
- Review the available implantable devices for the hemodynamic monitoring of PAH patients affected by right heart failure.
Suggested themes and article types for submissions: we will include original articles, perspective papers and reviews.
Dr. Silvia Papa
Dr. Giovanna Manzi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vascular diseases
- pulmonary arterial hypertension
- right failure
- afterload mismatch
- function capacity and exercise test
- imaging
